Votes sheila

Watson
Pharmaceuticals, Inc. (NYSE: WPI), a matchless specialty pharmaceutical
public limited company, announced that it has received final have a preference for from the
Amalgamated States (U.S.) Food and Anaesthetize Authority (FDA) on its Abbreviated
New Drug Application (ANDA) object of Ipratropium Bromide and Albuterol Sulfate
Inhalation Solution in the 0.5 mg/3 mg strength.

Watson’s Ipratropium Bromide and Albuterol Sulfate product is the
generic equivalent to Dey, L.P.’s DuoNeb(R), which is indicated for the
treatment of bronchospasm associated with chronic obstructive pulmonary
disease (COPD) in patients requiring more than one bronchodilator. For the
12 months ending September 2007, DuoNeb(R) and its generic equivalents had
total U.S. sales of approximately $265 million, according to IMS Healthfulness
observations. Watson intends to launch its Ipratropium Bromide and Albuterol
Sulfate product immediately.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading
specialty pharmaceutical company that develops, manufactures, markets,
sells and distributes marque and generic pharmaceutical products. Watson
pursues a growth scheme combining internal yield development, strategic
alliances and collaborations and synergistic acquisitions of products and
businesses.

For convergence releases and other company information, visit Watson
Pharmaceuticals’ Snare site at http://www.watsonpharm.com.

Bold-Looking Statement

Any statements contained in this press discharge that refer to expected
events or other non-recorded facts are forward-looking statements that
reflect Watson’s current position of existing trends and dope as
of the current of this story. Except as expressly required by law, Watson
disclaims any intent or obligation to update these forward-looking
statements. Actual results may differ substantially from Watson’s current
expectations depending upon a number of factors affecting Watson’s
business. These factors classify, among others, the impact of competitive
products and pricing; market acceptance of and continued demand for
Watson’s products; difficulties or delays in manufacturing; and other risks
and uncertainties ornate in Watson’s repeated public filings with the
Securities and Exchange Commission, including but not limited to Watson’s
Annual Probe on Conceive 10-K for the year ended December 31, 2006.

DuoNeb(R) is a registered trademark of Dey, L.P

Watson Pharmaceuticals, Inc.
http://www.watsonpharm.com